Norihito Shibata

Dr. Norihito Shibata

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Cell
Verified
Journal Article
Closed access
NSNathanael J. Spann
Nathanael J. Spann
LGLana X. Garmire
Lana X. Garmire
JMJeffrey G. McDonald
Jeffrey G. McDonald
DMDavid S. Myers
David S. Myers
SMStephen B. Milne
Stephen B. Milne
CGChristopher K. Glass
Christopher K. Glass

1 March 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
NONobumichi Ohoka
Nobumichi Ohoka
KOKeiichiro Okuhira
Keiichiro Okuhira
MIMasahiro Ito
Masahiro Ito
KNKatsunori Nagai
Katsunori Nagai
NSNorihito Shibata
Norihito Shibata
MNMikihiko Naito
Mikihiko Naito
Many diseases, especially cancers, result from aberrant or overexpression of pathogenic proteins. Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes. An alternative approach that may have utility in drug development relies on selective degradation of pathogenic proteins via small chimeric molecules linking an E3 ubiquitin ligase to the targeted protein for proteasomal degradation. To this end, we recently developed a protein knockdown system based on hybrid small molecule SNIPERs (Specific and Nongenetic IAP-dependent Protein Erasers) that recruit inhibitor of the apoptosis protein (IAP) ubiquitin ligases to specifically degrade targeted proteins. Here, we extend our previous study to show a proof of concept of the SNIPER technology in vivo. By incorporating a high affinity IAP ligand, we developed a novel SNIPER against estrogen receptor α (ERα), SNIPER(ER)-87, that has a potent protein knockdown activity. The SNIPER(ER) reduced ERα levels in tumor xenografts and suppressed the growth of ERα-positive breast tumors in mice. Mechanistically, it preferentially recruits X-linked IAP (XIAP) rather than cellular IAP1, to degrade ERα via the ubiquitin-proteasome pathway. With this IAP ligand, potent SNIPERs against other pathogenic proteins, BCR-ABL, bromodomain-containing protein 4 (BRD4), and phosphodiesterase-4 (PDE4) could also be developed. These results indicate that forced ubiquitylation by SNIPERs is a useful method to achieve efficient protein knockdown with potential therapeutic activities and could also be applied to study the role of ubiquitylation in many cellular processes.

1 April 2019 in Drug Discovery Today: Technologies
Verified
Journal Article
Open access
MNMikihiko Naito
Mikihiko Naito
NONobumichi Ohoka
Nobumichi Ohoka
NSNorihito Shibata
Norihito Shibata
The induction of protein degradation by chimeric small molecules represented by proteolysis-targeting chimeras (PROTACs) is an emerging approach for novel drug development. We have developed a series of chimeric molecules termed specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs) that recruit IAP ubiquitin ligases to effect targeted degradation. Unlike the chimeric molecules that recruit von Hippel-Lindau and cereblon ubiquitin ligases, SNIPERs induce simultaneous degradation of IAPs such as cIAP1 and XIAP along with the target proteins. Because cancer cells often overexpress IAPs-a mechanism involved in the resistance to cancer therapy-SNIPERs could be used to kill cancer cells efficiently.

23 June 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NSNorihito Shibata
Norihito Shibata
KNKatsunori Nagai
Katsunori Nagai
YMYoko Morita
Yoko Morita
OUOsamu Ujikawa
Osamu Ujikawa
NONobumichi Ohoka
Nobumichi Ohoka
MNMikihiko Naito
Mikihiko Naito

1 October 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
YDYosuke Demizu
Yosuke Demizu
NSNorihito Shibata
Norihito Shibata
THTakayuki Hattori
Takayuki Hattori
NONobumichi Ohoka
Nobumichi Ohoka
HMHiromi Motoi
Hiromi Motoi
MKMasaaki Kurihara
Masaaki Kurihara

30 August 2013 in Cancer Science
Verified
Journal Article
Open access
PDF file
KOKeiichiro Okuhira
Keiichiro Okuhira
YDYosuke Demizu
Yosuke Demizu
THTakayuki Hattori
Takayuki Hattori
NONobumichi Ohoka
Nobumichi Ohoka
NSNorihito Shibata
Norihito Shibata
MNMikihiko Naito
Mikihiko Naito
Manipulation of protein stability with small molecules has a great potential for both basic research and clinical therapy. Recently, we have developed a series of hybrid small molecules named SNIPER (Specific and Non‐genetic IAP‐dependent Protein ER aser) that induces degradation of target proteins via ubiquitin‐proteasome system. Here we report the activities of SNIPER(ER) that targets estrogen receptor alpha (ERα) for degradation. SNIPER(ER) induced degradation of ERα and inhibited estrogen‐dependent expression of pS2 gene in an estrogen‐dependent breast cancer cell line MCF‐7. A proteasome inhibitor MG132 and siRNA‐mediated downregulation of cIAP1 abrogated the SNIPER(ER)‐induced ERα degradation, suggesting that the ERα is degraded by proteasome subsequent to cIAP1‐mediated ubiquitylation. Intriguingly, after the ERα degradation, the SNIPER(ER)‐treated MCF‐7 cells undergo rapid cell death. Detailed analysis indicated that SNIPER(ER) caused necrotic cell death accompanied by a release of HMGB1, a marker of necrosis, from the cells. Following the ERα degradation, reactive oxygen species (ROS) was produced in the SNIPER(ER)‐treated MCF‐7 cells, and an anti‐oxidant N‐acetylcysteine inhibited the necrotic cell death. These results indicate that SNIPER(ER) induces ERα degradation, ROS production and necrotic cell death, implying a therapeutic potential of SNIPER(ER) as a lead for the treatment of ERα‐positive breast cancers.